Formulations
The test and reference formulations were evaluated simultaneously. The test formulation was provided by Zhejiang Hisun Pharmaceutical Co., Ltd. (250 mg/pill; Lot: 21803261; Purity: 95.0%-105.0%; Production date: March 26, 2018; expiry date: February, 2020). The reference formulation was from AstraZeneca UK Limited (IRESSA®, 250 mg/pill; Lot: MC979; Purity: 95.0%-105.0%; Production date: 2016.03; expiry date: February 2019).